Yang Shuai, Duan Hongwei, Yan Zhenxing, Xue Chen, Niu Tian, Cheng Wenjing, Zhang Yong, Zhao Xingxu, Hu Junjie, Zhang Lihong
College of Veterinary Medicine, Gansu Agricultural University, Lanzhou 730070, China.
Gansu Key Laboratory of Animal Generational Physiology and Reproductive Regulation, Lanzhou 730070, China.
Nutrients. 2025 Jan 7;17(2):203. doi: 10.3390/nu17020203.
BACKGROUND/OBJECTIVES: Ulcerative colitis (UC) is a chronic and easily recurrent inflammatory bowel disease. The gut microbiota and plasma metabolites play pivotal roles in the development and progression of UC. Therefore, therapeutic strategies targeting the intestinal flora or plasma metabolites offer promising avenues for the treatment of UC. Luteolin (Lut), originating from a variety of vegetables and fruits, has attracted attention for its potent anti-inflammatory properties and potential to modulate intestinal flora.
The therapeutic efficacy of Lut was evaluated in an established dextran sodium sulfate (DSS)-induced colitis mice model. The clinical symptoms were analyzed, and biological samples were collected for microscopic examination and the evaluation of the epithelial barrier function, microbiome, and metabolomics.
The findings revealed that Lut administration at a dose of 25 mg/kg significantly ameliorated systemic UC symptoms in mice, effectively reduced the systemic inflammatory response, and significantly repaired colonic barrier function. Furthermore, Lut supplementation mitigated gut microbiota dysbiosis in a UC murine model, increasing the abundance of , , and while decreasing and levels. These alterations in gut microbiota also influenced plasma metabolism, significantly increasing phosphatidylcholine (PC), 6'-Deamino- 6'-hydroxyneomycin C, and gamma-L-glutamyl-butyrosine B levels and decreasing Motapizone and Arachidoyl-Ethanolamide (AEA) levels.
This study reveals that Lut supplementation modulates intestinal inflammation by restoring the gut microbiota community structure, thereby altering the synthesis of inflammation-related metabolites. Lut is a potential nutritional supplement with anti-inflammatory properties and offers a novel alternative for UC intervention and mitigation. In addition, further studies are needed to ascertain whether specific microbial communities or metabolites can mediate the recovery from UC.
背景/目的：溃疡性结肠炎（UC）是一种慢性且易复发的炎症性肠病。肠道微生物群和血浆代谢物在UC的发生和发展中起关键作用。因此，针对肠道菌群或血浆代谢物的治疗策略为UC的治疗提供了有前景的途径。木犀草素（Lut）源自多种蔬菜和水果，因其强大的抗炎特性和调节肠道菌群的潜力而受到关注。
在已建立的葡聚糖硫酸钠（DSS）诱导的结肠炎小鼠模型中评估Lut的治疗效果。分析临床症状，并收集生物样本进行显微镜检查以及评估上皮屏障功能、微生物组和代谢组学。
研究结果显示，以25mg/kg的剂量给予Lut可显著改善小鼠的全身性UC症状，有效降低全身炎症反应，并显著修复结肠屏障功能。此外，补充Lut可减轻UC小鼠模型中的肠道微生物群失调，增加 、 和 的丰度，同时降低 和 的水平。肠道微生物群的这些变化也影响血浆代谢，显著提高磷脂酰胆碱（PC）、6'-脱氨基-6'-羟基新霉素C和γ-L-谷氨酰-酪氨酸B的水平，并降低莫他匹宗和花生四烯酰乙醇胺（AEA）的水平。
本研究表明，补充Lut通过恢复肠道微生物群落结构来调节肠道炎症，从而改变炎症相关代谢物的合成。Lut是一种具有抗炎特性的潜在营养补充剂，为UC的干预和缓解提供了一种新的选择。此外，需要进一步研究以确定特定的微生物群落或代谢物是否能介导UC的恢复。
